Advancell raised an oversubscribed $315 million Series D round to accelerate its global radiopharma strategy, funding late-stage clinical development and expanding isotope supply and manufacturing infrastructure. The funding is designed to move Advancell toward a fully integrated model that links isotope production with radiopharmaceutical development, a structure meant to reduce supply bottlenecks and support consistent commercialization timelines. The company frames the round as a way to strengthen clinical execution while also building the downstream capabilities needed for predictable manufacturing. In a market where radionuclide supply has become a gating factor for scaling, the Advancell financing signals sustained investor appetite for integrated radiopharma platforms with late-stage readiness.